Alnylam Pharmaceuticals
ALNY
281 hedge funds and large institutions have $8.69B invested in Alnylam Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 108 increasing their positions, 78 reducing their positions, and 44 closing their positions.
42% more call options, than puts
Call options by funds: $113M | Put options by funds: $79.5M
38% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 78
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
13% more capital invested
Capital invested by funds: $7.7B → $8.69B (+$995M)
2.4% less ownership
Funds ownership: 99.58% → 97.18% (-2.4%)
3% less funds holding
Funds holding: 290 → 281 (-9)
20% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$160M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$109M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$66.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$55.4M |
| 5 |
BlackRock
New York
|
+$44.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$80.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$70.1M |
| 3 |
RI
RTW Investments
New York
|
-$34.1M |
| 4 |
HM
HealthCor Management
New York
|
-$34M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28.9M |
ALNY Hedge Fund Activity: Q3 2019 in Review
281 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2019, worth a combined $8.69B — up 13% from $7.7B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of ALNY and 35 opened new positions — a net loss of 9 holders — while 78 trimmed existing stakes and 108 added.
The largest buyer was Baillie Gifford & Co, adding an estimated $160M. The largest seller was Maverick Capital, cutting an estimated $80.2M.
- 281 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2019, down from 290 in Q2 2019.
- Funds reported $8.69B of Alnylam Pharmaceuticals stock for Q3 2019, up 13% quarter-over-quarter.
- 35 funds opened new Alnylam Pharmaceuticals positions in Q3 2019 and 44 closed out, a net change of -9 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2019 was Baillie Gifford & Co, an estimated $160M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2019 was Maverick Capital, an estimated $80.2M sold.
Based on aggregated 13F filings for Q3 2019.